Press release
Dec 3, 2018

Sosei Heptares – the world leader in GPCR drug design launches new name and corporate identity

Tokyo, Japan and London, UK, 3 December 2018 – Sosei Group Corporation (“Sosei” or “the Company”; TSE: 4565), is delighted to announce today that it has re-branded and re-launched its main operating business as Sosei Heptares. A new company website is launched today at

The decision to combine the names of Sosei and Heptares is designed to retain the strong brand identities of both companies in domestic and international markets, and particularly in Japan and the UK where the companies originate.

The re-launch also marks the start of a new chapter for the company following a period of significant change and growth that began with Sosei’s acquisition of Heptares Therapeutics in February 2015.

This acquisition was transformational, enabling the new group to leverage the world leadership that Heptares had established in GPCR-focused structure-based drug design (SBDD) with experienced commercial management at Sosei to create an international biopharmaceutical group advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas. Since then, the Company has enhanced its technology platform, advanced candidates through its pipeline into clinical development, added significant new partnership deals and collaborations, and created a new GPCR-SBDD research center of excellence in Cambridge, UK, which was formally opened in October.

Shinichi Tamura, Executive Chairman and Founder of Sosei, said: “In re-launching the company as Sosei Heptares, we are reflecting the great cooperation since 2015 of two teams with complementary expertise. Our decision to adopt a new global brand that combines the best of both names and identities represents a synergistic fusion of our Japanese-Anglo heritage. It also signifies our intent to work together as one integrated company with a single purpose towards achieving our mission: to make a significant contribution to improving the quality of life and health of people around the world by applying our world-leading technology to discover, design and develop innovative and effective medicines for patients worldwide.”